INTRODUCTION
Diversity in the set of neurons in the brain is defined partly by differences in the proteins that they express. For example, cortical and hippocampal inhibitory interneurons can be divided into B15 subclasses defined by their anatomy, electrophysiological properties dictated by their expression of ion-channel proteins, and expression of different calcium-binding proteins and neuropeptides 1, 2 . Furthermore, during the development of the nervous system, neurons and glial cells change the pattern of proteins they express. This occurs in the nucleus where changes in transcription factors or calcium-binding protein expression control the production of different cell lineages 3, 4 ; in the cytoplasm where calcium-binding proteins become increasingly important to buffer activity-induced rises of [Ca 2+ ] i during development 5 ; and in the cell membrane where the expression of voltage-gated currents 6 , neurotransmitter transporters 7 and transmitter-gated channels 8 is altered to support the function of the cell. Therefore, it is often important to define the subtype or developmental stage of a cell being recorded from by characterizing which proteins it expresses.
Single-cell PCR, in which mRNA is recovered from a whole-cell pipette used to record electrical signals from a cell, has been used to correlate cell phenotype with protein expression [9] [10] [11] [12] , but suffers from four disadvantages. First, the technique is technically challenging, owing to the small amount of mRNA retrieved and the fact that during prolonged recording mRNA breakdown can occur. Second, the level of mRNA might not correlate well with the amount of protein expressed. Third, neurons in brain slices are often wrapped by glia, and it is hard to avoid the possibility that some glial cytoplasm is harvested with the neuronal cytoplasm, which might generate false-positive results. Fourth, false-negative results may occur if insufficient mRNA is harvested when the cytoplasm is sucked into the pipette 13 . An alternative approach is to make mice that express a fluorescent protein, such as enhanced green fluorescent protein (eGFP), under the control of a cellspecific promoter, so that the experimenter can choose to record only from cells of a particular type [14] [15] [16] [17] . However, such mice take time to generate and, unless the construct used to drive eGFP expression recapitulates exactly the control sequences regulating the promoter in vivo, then the eGFP may be expressed in cells in which the promoter is normally inactive 18, 19 .
To overcome these problems, it is desirable to combine electrophysiological recording of cells in brain slices with post-recording antibody labeling of the proteins that they express [20] [21] [22] . This offers a major advantage over single-cell PCR in that, using specific antibodies, it provides unambiguous identification of protein expression in the recorded cell, and avoids the possibility of contamination from proteins that are expressed in neighboring cells. However, although immunolabeling of cells in culture or in thin cryostat sections is straightforward, it is more difficult in the brain slices used for electrophysiology, because of their thickness (200-300 mm), which limits antibody penetration and can require cryostat resectioning for labeling of cells more than B10 mm below the surface of the slice 20 . Furthermore, although detergent, such as Triton X-100, is often employed to increase antibody penetration into slices, even when the epitope is extracellular, this is not possible when using antibodies that recognize lipid epitopes, such as the sulfatide O4, which defines a developmental stage of oligodendrocytes. Here, we describe a protocol that we have applied successfully 23 , after whole-cell clamping of oligodendrocytes, astrocytes and their precursors in brain slices, to label neurotransmitter receptors and myelin basic protein in the cell membrane, the lipid sulfatide O4, the membrane proteoglycan NG2, the cytoplasmic structural protein glial fibrillary acidic protein (GFAP), and the nuclear transcription factor Olig2. The protocol typically allows labeling at a depth of up to 50 mm below the surface of the slice.
Although we have so far only employed this protocol to define cell identity and study changes in brain cell properties during development, it could easily be extended to investigate changes induced by pathological conditions, such as ischemia, and applied to other tissues in which electrical recording of cells is performed in tissue slices.
MATERIALS

REAGENTS
. Sprague-Dawley rats: postnatal day 7-28 ! CAUTION All animal experiments are to be performed in accordance with relevant authorities' guidelines and regulations . Pre-made phosphate buffered saline (PBS) tablets (Oxoid) . Sodium azide (NaN 3 ; Sigma) ! CAUTION Highly toxic, avoid inhalation and skin contact (as it will compete with O 2 for hemoglobin binding sites)
. Paraformaldehyde (PFA; Sigma) ! CAUTION This is a known toxin and carcinogen. Avoid inhalation and contact with eyes, skin and mucous membranes . Triton X-100 (BDH) ! CAUTION Triton is a strong detergent. Avoid contact with skin and eyes; use gloves . Serum from the animal species that the secondary antibody was raised in, e.g., goat serum (Vector) . Primary and secondary antibodies (various suppliers, according to antibody used)
. Antifade glycerol-based mounting medium, such as Citifluor (Citifluor) . Nail varnish (preferably one which dries in a few seconds) . DAPI (4¢,6-diamidino-2-phenylindole; Molecular Probes) . Non-specific immunoglobulins: antibodies not raised against a particular protein, but purified from the blood of the host animal in which the primary antibodies used to label particular proteins are raised (Vector) . Lucifer . Recording chamber with 1 ml volume . Peristaltic pump (Masterflex) or gravity-fed (homemade) perfusion system . Patch-clamp head-stage and amplifier (e.g., Axon) . Micro-manipulators (e.g., Luigs and Neumann) . Two-stage electrode puller, either vertical or horizontal, to make patch pipettes. We use a vertical puller (PC-10; Narishige)
. 24- . Paintbrushes (ProArte), as many as the number of antibodies used.
These should preferably be made from acrylic fibres because these tend to stick less to the tissue. The size of the paintbrush should be correlated with the size of the tissue. For example, we use brushes from numbers 0-2 for the small cerebellar slices and 1/8'' flat brushes for cerebral cortical slices.
. Confocal microscope (e.g., LSM 510; Zeiss), microscope slides and coverslips (use appropriate thickness for the objective used; VWR)
. An opaque (black) box in which the 24-or 48-well plate can be placed. If no suitable opaque box is available, a transparent box can be covered in aluminum foil to reduce bleaching of the dyes used for cell filling and antibody labeling.
. Parafilm (Azwell) . Syringe filters, 0.22 mm (Millimex GP) . Syringes, 20 ml (Terumo)
REAGENT SETUP Intracellular dye-filling recording solution Add a fixable fluorescent dye into an internal solution that fits your experimental purpose the best, typically a K + -based internal for mimicking physiological conditions or a Cs + -based internal to improve voltage-clamp quality 23 . The dye that we use most frequently is Lucifer yellow CH, as it is economical and works satisfactorily. However, we have also used biocytin (especially to study gap junctional coupling) or the Alexa dyes with equal success. When using 2 mM Lucifer yellow CH (1 mg ml -1 ), add the dye to the internal solution of interest (typically 20 ml is made up), sonicate for a few seconds to dissolve the dye, and filter if necessary through a 0.22 mm filter attached to a 20 ml syringe (all at room temperature (20-25 1C) ). The Alexa dyes are expensive but very bright, and so can be used at low concentration (0.2 mg ml -1 ); it is possible to just fill the tip of the electrode with the dye-filled solution (see PROCEDURE, Day 1, for how to do this), and then backfill the pipette with the same internal solution but lacking the dye. Alternatively, neurobiotin can be used at 1.5 mg ml -1 for dye filling, but to study gap junctional coupling use a higher concentration of neurobiotin, e.g. 5-10 mg ml -1 . m CRITICAL The composition of the electrode solution needs to be designed taking into account the osmotic pressure added by the neurobiotin or dye present. 0.1 M PBS Dissolve PBS tablet in distilled water (1 tablet per 100 ml) 4% paraformaldehyde (PFA) solution Dissolve 20 g PFA in 500 ml of 0.1 M PBS slowly on a heated magnetic stirrer, wait till the solution reaches 60 1C, add a few drops of 10 M NaOH solution until the PFA solution turns clear and then filter the solution. Aliquot into 5 ml tubes and freeze at -20 1C for up to a year. Thaw on the day of use and throw away any unused PFA remaining from that aliquot. ! CAUTION Paraformaldehyde is a known toxin and carcinogen. Avoid inhalation and contact with eyes, skin and mucous membranes. 1% NaN 3 stock solution Dissolve 10 g of NaN 3 in 1 l of distilled water ! CAUTION NaN 3 is highly toxic. Avoid inhalation or skin contact (as it will compete with O 2 for hemoglobin binding sites). 0.1 M PBS with 0.05% NaN 3 Dilute the NaN 3 stock solution 20-fold with distilled water and than dissolve the PBS tablets in that. For example, to make 500 ml: dissolve 5 PBS tablets in 25 ml of the 1% NaN 3 stock mixed with 475 ml of distilled water. 5% Triton X-100 stock solution in PBS Add 1 ml of Triton X-100 (it is very viscous, so pipette slowly so as not to generate bubbles) into 19 ml of the 0.1 M PBS with 0.05% NaN 3 solution, and stir gently until dissolved ! CAUTION Triton X-100 is a strong detergent. Avoid contact with skin and eyes; use gloves. Blocking and permeabilizing solution: 10% goat (or other animal) serum, 0.5% Triton X-100, 0.05% NaN 3 , and 0.1 M PBS For 20 ml of solution, add 2 ml of 5% Triton X-100 stock solution and 2 ml of goat serum (or the serum from the animal that your secondary antibody was raised in) to 16 ml of the 0.1 M PBS with 0.05% NaN 3 solution. When labeling lipid antigens, such as the sulfatide O4, omit the Triton X-100 (use 18ml of the 0.1 M PBS with 0.05% NaN 3 solution) m CRITICAL Make up fresh before use. Slicing medium Normal Krebs' solution (for example: NaCl 126 mM, KCl 2.5 mM, NaHCO 3 24 mM, NaH 2 PO4 1 mM, CaCl 2 2.5 mM, MgCl 2 2 mM, glucose 15 mM; gassed with 95% O 2 / 5% CO 2 ), with the addition of 1 mM kynurenic acid (Sigma) to block glutamate receptor-mediated cell damage during the slicing process. EQUIPMENT SETUP Electrophysiology setup Upright fixed-stage differential interference contrast microscope with 4Â and 40Â or 60Â objectives, a halogen lamp and filter sets suitable for the excitation and emission wavelengths of the fluorescent dye used. A recording chamber with 1 ml volume that fits the stage of the microscope, peristaltic pump or gravity-fed perfusion system, patch-clamp head-stage and amplifier, and micro-manipulators. the skull by cutting between the eyes, then making lateral cuts on either side of the head from the anterior to the posterior. Lift the excised region of the skull with forceps, quickly remove the whole brain and place it in ice-cold oxygenated slicing medium. Dissect out the brain area of interest and superglue it onto a block for cutting. Cut vibrotome sections of 225 mm (the vibration amplitude and frequency, and the speed of advancing the brain, vary between slicers; optimal values need to be chosen for each slicer). As soon as the slices are cut, transfer them (using the cut-off Pasteur pipette) into the slice storage chamber filled with oxygenated slicing medium, and allow them to settle for an hour prior to recording. The slices can be used up to 9 h after slicing.
PROCEDURE
2| Take an aliquot of PFA from the freezer and thaw it at room temperature (20-25 1C).
3| Pull electrodes that match your purpose the best, making the resistance as large as possible without prejudicing satisfactory recording of the membrane currents. Choice of whole-cell pipette size: There is a trade-off between obtaining a good access resistance (which requires a large pipette diameter) and keeping the cell soma intact and attached to the rest of the cell after removal of the pipette (which is easiest using small diameter pipettes). For cells which have a soma diameter of B5-10 mm, such as oligodendrocytes and small neurons, the highest success rate comes from having pipettes with a resistance of 6-7 MO. However, cells with larger somata (neurons such as Purkinje and pyramidal cells, as well as large astrocytes) can be successfully recorded from, and subsequently labeled using, larger pipettes, around 2-4 MO. When a low series resistance is essential to record large membrane currents, it is possible to use lower resistance pipettes and still leave the cell soma attached to the cell after electrode removal, although the success rate for satisfactory electrode removal is reduced.
4| For recording and dye filling, take a brain slice out of the slice storage chamber using the cut-off Pasteur pipette, and put it into a recording chamber under the microscope. Continuously perfuse the recording chamber with oxygenated artificial cerebrospinal fluid (Krebs' solution), using gravity or a pump-driven perfusion system. Hold the slice in place in the bath by covering it with a ''harp'', made of a parallel array of nylon threads (separated from each other by 0.5-1.0 mm) strung on a U-shape frame made from platinum wire. Look at the slice through the microscope at low magnification (4Â), make a note of the orientation of the slice for your records (for an example see 5| Fill a pipette with intracellular dye-filling recording solution. If using an Alexa dye or neurobiotin, put the pipette upside down (i.e. pointed end upwards) in an Eppendorf tube containing 20 ml of the dye solution, and the tip will fill up by capillary pressure. Then, using a cannula attached to a syringe containing internal solution without dye, backfill the pipette with this internal solution lacking dye. For Lucifer yellow CH just fill the pipette normally, i.e. the dye is in all of the internal solution.
6| Approach cells with the pipette, blowing solution out of the pipette to clean the cell surface. We have never found a high background from dye that is blown out of the pipette while approaching the cell of interest, because it is not taken up significantly by neighboring cells. When the pipette touches the cell of interest, stop blowing and suck a little and at the same time hyperpolarize the cell membrane. Wait until at least a gigohm (GO) seal has formed, wait a further 30-60 sec for extracellular ions sucked into the pipette to diffuse up the pipette, then apply negative pressure to rupture the cell membrane beneath the pipette and go into whole-cell mode. The dye will now diffuse into the cell. In experiments where the wish is just to dye-fill the cell and then proceed with the immunohistochemistry, one should try to keep the recordings short; B10 min should be enough. However, in most cases, longer recordings are required to study the cell's electrophysiological properties in detail. This is possible, but the longer the recording, the lower is the success rate for the dye being retained in the cell after removing the pipette from the cell, perhaps because the membrane is more leaky after long recordings. We have, however, kept the success rate quite high even with 1 h recordings involving exposing the tissue to ischemia 23 . The patched cell will be near one surface of the slice, which must be identified for correct mounting of the slice for subsequent confocal microscopy. (a) For an asymmetrical slice, such as the cerebellar slices shown here, the surface orientation (i.e. which side is ''up'' and nearest the patch electrode) is defined by the shape of the slice, and all that is needed is to choose which of the two possible shapes is relevant: place a tick on the appropriate diagram (e.g., the left one as here) and mark the cell position on the figure so that locating it using the confocal microscope is faster. (b) For a symmetrical slice, like this transverse forebrain slice, it is necessary to introduce an asymmetry to define the surface orientation, which is done by making a cut in the slice with an electrode. Then the cell position is marked as before. Brain pictures from ref. 26 .
removing the pipette from the cell soma. The higher the seal resistance, the better is the success rate for removing the pipette without destroying the soma. To start removing the electrode, depolarize the cell to 0 mV. With a seal resistance of 10-30 GO, the best way to remove the pipette from the soma is by pulling away and slowly lifting the pipette upward at the same time as if you were making an outside-out patch. Looking at the cell you should see a patch of membrane sprouting out of the soma and adhering to the pipette, and this thread of membrane will then detach from the soma leaving the cell soma intact. In the case of a lower seal resistance, it is often good to apply some positive pressure to the pipette, as well as wiggling the pipette sideways, and up and down, to loosen the pipette from the soma. In a bad scenario, the cell soma is well attached to the electrode, and the ''thread'' does not appear. In these extreme cases it is possible to tap lightly on the stage or on the pipette holder to shake the pipette off; however, this often leads to the cell body detaching from the cell with the pipette. In some cases with a low seal resistance it is possible to remove the pipette quickly from the cell soma, instead of slowly; however, this is risky because it can make the dye leak out. One should try these alternative methods only when the first approach is not working.
8| Mark the location of the cell on a map of the tissue slice (for an example see Fig. 1a ,b) so that it can easily be found later. The location is best specified using a low power objective. In addition, if recording from more than one cell in the same slice, it is important to sketch the morphology of the cell (as revealed by the dye fill, observed by fluorescence with the slice still on the recording microscope), because marking the location in the slice does not always give enough information to define which cell was which. To be able to relocate the cell, it is also important to mark the orientation of the tissue slice to know which of the two slice surfaces the cell was recorded from. In the case of an asymmetrical slice, like the cerebellum, mark on a diagram (see Fig. 1a ) which side is upwards (i.e. the side from which the electrode was attached) by noting which of the two possible slice shapes is seen when looking down the microscope. This cannot be done for symmetrical slices (e.g., the transverse forebrain slice in Fig. 1b) , and then it is important to cut the tissue on one side (for example with a pipette) to introduce an asymmetry, and to mark on a diagram for each slice where the cut is, to define the surface orientation correctly (see Fig. 1b ).
9| After drawing the cell and marking the diagram of the slice, put the slice (in Krebs' solution) in an empty well in the 24-well plate. Then fill another well in the same plate with 4% PFA solution, remove the slice from the Krebs' solution with a paintbrush and put it gently into the PFA. Insert the 24-well plate into the ''black box'', so the slice is not exposed to light, and then put it on a rotary shaker at 60-80 r.p.m. for one hour at room temperature. Then proceed to step 11 (washing). Now it is possible to repeat Steps 4-9 if recording from more slices on the same day. m CRITICAL STEP Mark the lid of the 24-well plate with the cell number and date over each well containing slices.
10| At the end of the day, fix some of the remaining (not recorded from) slices that have no filled cells in them so they can be used as control slices for the immunohistochemistry (see Box 1, and Table 1 for the number of unfilled slices to fix). Mark on the lid of the plate over the well where the control slices are kept.
' PAUSE POINT The slices in PFA can be stored at 4 1C overnight for fixation, instead of shaking at room temperature for one hour, if necessary.
11| After an hour (or overnight at 4 1C) in PFA, wash the slice(s) 3 Â 15 min in 0.1 M PBS made freshly that day. Use a paintbrush (dipped previously in PBS, so it is wet and without air bubbles) to transfer the slices between wells. ' PAUSE POINT after the last wash, slices can be stored at 4 1C for up to 5-7 days in 0.1 M PBS with 0.05% NaN 3 . The longer the slices are kept, the worse the tissue condition gets and this often reduces immunoreactivity and increases background for the antibody labeling. Remember to always keep the plate containing the slices in the ''black box'' . 13| For small tissue slices use a 48-well plate and add, into the same number of wells as you have slices, 200-500 ml of freshly made blocking and permeabilizing solution. For larger slices use a 24-well plate and place up to 1 ml of solution in each well. To transfer the slices from the washing 0.1 M PBS to the blocking and permeabilizing solution use a paintbrush. Dip the paintbrush in PBS to wet the brush, removing all air bubbles that form (because the tissue will adhere to the brush if air bubbles are present). Then gently remove the slice from the PBS and immerse it in the well with the blocking solution; continue like this for all the slices. Write the date and number of each cell in the slice on the lid of the plate, also mark where the control slices are. Put the plate in the ''black box'' and place it on a shaker for 4-6 h (at 60-80 r.p.m., at room temperature), depending on the thickness of the slice. For example, 225 mm slices will require about 5 h.
14| Dilute the primary antibody in 0.1 M PBS with 0.05% NaN 3 at the concentration for which reliable results have been found (see Box 2 for details on determining the concentration of antibody to use). Calculate the amount of antibody-containing solution as follows: each well in a 48-well plate needs a minimum of 200 ml and each well in a 24-well plate needs at least 500 ml of the antibody solution. 15| Prepare the solutions for the control experiments. Have one blank control, i.e. a slice with no primary antibody to which you will only apply secondary antibody in Step 22 (apply all the secondary antibodies if using more than one primary antibody). In addition, when using more than one primary antibody, make a control slice for each primary antibody (to check the specificity of the secondary antibodies), to which that primary and all the secondary antibodies are applied in Step 22 (see Box 1, and for more details on the number of control slices to use see Table 1 ). These controls should be carried out every time an experiment is done. m CRITICAL STEP When using several primary antibodies, they have to come from different host animals.
16| If you have not done so before, prepare and include controls for the specificity of the primary antibody. These need only to be done once for a given primary antibody. If the peptide to which the antibody was raised is available, preabsorb the antibody 
BOX 1 | TESTING FOR ARTEFACTS: CONTROL EXPERIMENTS FOR ANTIBODY NON-SPECIFICITY
Specificity of the secondary antibodies 1. Are the secondary antibodies specific, i.e. are you sure they do not attach to sites other than the primary antibody? This is checked using a blank control, i.e. labeling the slice without a primary antibody (see Table 1 ). If this shows the same immunolabeling as the slice with the primary antibody, then the secondary antibody is binding to something other than the primary. There should be little binding in the blank control. However, in slices fixed after recording (i.e. not from perfusion-fixed animals) the secondary antibodies often (almost always) label blood vessels. 2. The use of more than one primary antibody calls for extra control experiments. In addition to the slices containing filled cells being treated with all the primary antibodies, a set of slices that were not recorded from are labeled with each single primary antibody alone but then treated with all the secondary antibodies. This is to make sure that one secondary antibody is not binding to more than one primary antibody. In that situation one would erroneously get an apparently ''perfect'' co-localization of the labeling of two antibodies. (Of course, when using multiple primaries, one has to have them raised in different animals, for example, mouse, rabbit and sheep, to prevent the secondary recognizing more than one primary). Specificity of the primary antibodies 3. Antibodies are purified immunoglobulins that have been raised to recognize a certain epitope; however, these are big proteins and there is always scope for the protein to get ''stuck'' to some area in the tissue other than the desired epitope, leading to unspecific staining by the primary antibody. This can be tested for in two ways (see also Table 2 ). First, examine the labeling obtained after preabsorbing the antibody with the peptide to which it was raised (if this is available). We preabsorb in an Eppendorf tube (on a rotary shaker at 60-80 r.p.m. for 2-8 h), using the peptide at a 5 to 10-fold higher concentration (in g l -1 ) than the antibody: no labeling should be seen after the preabsorption. Alternatively, if no peptide is available, buy purified immunoglobulins (from the same host animals) that have not been deliberately raised against any protein, i.e. just purified IgG or IgM from the blood of the animals. Using these immunoglobulins at the same concentration as the primary antibody tests whether there is some non-specific binding that is inherent to immunoglobulins. If labeling in this slice comes out to be the same as the one with the primary, but the blank slice (to which no primaries were applied) is not the same, then that shows that the primary antibody is not specific (note that similar labeling in the IgG/IgM slice and the experimental slice could reflect non-specificity of either the primary or the secondary antibody, and comparison with the blank slice is necessary to establish where the problem lies). 4. To further test for specificity of the primary antibody one can perform the immunohistochemistry on a tissue where the expression of the protein of interest is known. If the antibody does not label where it should then there is something suspicious going on. In addition, one should test the antibody on a tissue where it is not supposed to be expressed and see if there is still detectable staining, ideally in an animal in which the protein of interest has been knocked out. To start to understand cross-reactivity of primary antibodies, if the antibody has been raised to a defined peptide sequence, then searching for other proteins containing the same peptide sequence in a protein database might provide an explanation for the labeling seen. For further consideration of this issue see ref. 27 . When should each specificity test be performed? For each primary antibody, (3) and (4) only need to be done once; however, (1) and (2) should always be performed for every experiment. with that peptide and/or check whether similar labeling is produced by a non-specific immunoglobulin (i.e. not deliberately raised against any protein of interest in your experiment) that is from the same species as your primary antibody of interest and at the same concentration. This controls for unspecific binding of the immunoglobulin (IgG or IgM) molecule: for more details see Table 2 and Box 1.
17| Add the antibody mixture into each well where a dye-filled slice will go; for the negative control with no primary antibodies use only 0.1 M PBS with 0.05% NaN 3 .
18| After incubating the slices in the blocking and permeabilizing solution (Step 13), transfer the slices using paintbrushes into a new 24-or 48-well plate containing the primary antibody solutions, starting on the negative controls and changing the brush between antibodies if using more than one. Remember to wet the brushes first in PBS. Afterwards, wash the brushes in hot water and rinse in distilled water. Wrap Parafilm around the edges of the plates to minimize evaporation.
19|
Incubate the primary antibody in the ''black box'' on a shaker (60-80 r.p.m.) at room temperature for 12-15 h or overnight.
Day 3: Secondary antibody labeling of the slices 20| Wash the slices 4 times for 20 min in 0.1 M PBS. Use a brush to transfer the slices, remembering to always change brush between antibodies and to start on the negative controls, so that there is no contamination of different antibodies between wells. Wash the brushes well between washes, first with hot water and then rinse in distilled water.
21| During the washing, make up the secondary antibody solution. See Box 2 for suitable antibody dilutions. Normally, when using secondary antibodies from Molecular Probes, we use a dilution of 1:200-1:500. Incubation time and concentration are interlinked, so a lower concentration implies a longer incubation time and vice versa. Secondary antibodies should go in every well, i.e. including those for the controls (see Box 1 and Table 1 ).
22| After the washing, transfer the slices into a new 24-or 48-well plate containing the secondary antibody solutions. Do this carefully with a brush, starting with the negative controls and changing brush between primary antibodies. Seal the plate with Parafilm to reduce evaporation. Put in the ''black box'' and on the shaker at 60-80 r.p.m. for 4-8 h at room temperature. ' PAUSE POINT After shaking for 30 min the slices can be put in the fridge overnight or for up to 48 h; if using a long incubation in this way, reduce the concentration of secondary antibody. 
BOX 2 | ANTIBODY DILUTIONS
When starting to use a new primary antibody, first try to either find a previous paper where the antibody has been used on fixed tissue, or get information from your supplier on a suitable dilution range. 1. Based on a previous paper: make three dilutions, one 5-10 times more diluted than that which the paper used, one the same, and the third less diluted (e.g., 0.5 times less). If the more diluted solution works, try to dilute it further (as this will save money). 2. Based on supplier information: normally suppliers give a range of dilutions, such as from 1:100-1:500. Again make three dilutions, one at the highest of the range of dilution, one at the lowest of the range, and then one 2-fold more diluted than the supplier's range. 3. Sometimes no information about useful dilutions exists for fixed tissue. If there is information for western blotting, then use double that concentration and try also two dilutions around that value. So if western blotting uses 1:1000, then make dilutions of 1:100, 1:500 and 1:1000. 4. If no information exists in any usable form, start with dilutions of 1:50-1:100, 1:500 and 1:1000.
In general, when a dilution that works has been found, one could try to dilute slightly, for example if 1:500 worked but not 1:1000, then 1:700 could be tried. Similar dilution trials can be made for secondary antibodies, but normally we have used the concentrations that the companies specify, although it is possible to dilute them further. Dilutions and time are interrelated, so with a longer incubation time a lower concentration of antibodies can be used. a Suppose you are using three primary antibodies, which happen to be an IgG raised in rabbit, an IgM from mouse and an IgG from guinea pig. Obtain peptides for preabsorption and/or non-specific immunoglobulins of the same type and species, and label three slices each with them as shown above.
23| Wash the slices 4 times for 20 min in 0.1 M PBS. Use a brush to transfer the slices, remembering always to change brush between primary antibodies and to start on the negative controls, so there is no contamination between wells of different primary antibodies. Wash the brushes well between washes, first with hot water and then rinse in distilled water. ' PAUSE POINT After 2 washes slices can be put in 0.1 M PBS with 0.05% NaN 3 and stored at 4 1C for a few days until it is a suitable time to mount the slices. When using more than one primary antibody, they can all be applied simultaneously as they are raised in different animals, providing the antibodies are used at low concentrations. Alternatively, apply them sequentially by going through Steps 14-23 for each one: this is preferred when using antibodies at high concentrations.
24| If testing whether a nuclear protein is expressed (if not go to Step 26) , also label the slices for DAPI. Make up 300 nM DAPI solution in 0.1 M PBS and incubate the slices for 10-20 min in the ''black box'' on the shaker (60-80 r.p.m.) at room temperature. Transfer slices using brushes and be careful to use a new brush for each antibody. m CRITICAL STEP DAPI labeling is essential because often, when taking the pipette away from the cell, the nucleus might be removed, making it impossible to conclude whether the cell is negative for the nuclear protein because the nucleus is not labeled or because the nucleus is missing. Figure 2 shows an astrocyte filled with Lucifer yellow from the whole-cell pipette and labeled after recording for GFAP 23 . The morphology of the cell revealed by Lucifer yellow together with the GFAP labeling defines the cell as an astrocyte. Figure 3 shows an oligodendrocyte lineage cell with a morphology revealed by Lucifer filling in which some processes align with axons, and some do not. This, together with the labeling by antibody to the lipid sulfatide O4, defines the cell as being an immature oligodendrocyte that is only starting to myelinate axons 23 . This figure shows that, even with no Triton X-100 permeabilization (which would destroy the lipid where the O4 epitope resides), good labeling can be obtained because the antibody is recognizing an extracellular epitope and because prolonged antibody incubation with tissue shaking is employed (see above). Figure 4 shows the use of two antibodies and DAPI to label the nucleus, on the same recorded cell. The Lucifer yellow fill reveals a small cell with processes radiating in all directions. This, together with the antibody labeling to the proteoglycan NG2 and to the oligodendrocyte-specific transcription factor Olig2, establishes that the cell is an oligodendrocyte precursor. Cells which are positive for Olig2 and not NG2 are immature and mature oligodendrocytes.
Finally, in Figure 5 we show the use of the protocol to define the presence of a current-generating membrane protein, the NMDA receptor. The Lucifer yellow fill reveals the morphology of a mature oligodendrocyte, whereas the subsequent labeling for the NR1 subunit of NMDA receptors demonstrates that NMDA receptors are present in the cell and so could account for NMDA-evoked currents recorded during whole-cell clamping 23 . 
